Table 4 Safety outcomes
|  | Anti-CGRP mAbs (n = 86) | BoNT-A (n = 97) | p-value |
|---|---|---|---|
SAE, n (%) | 0 (0.0) | 0 (0.0) | - |
Discontinuation due to AE, n (%) | 1 (1.2) | 0 (0.0) | 0.470 |
Arthralgia | 1 (1.2) | 0 (0.0) | - |
Discontinuation due to other reasons, n (%) | 10 (11.6) | 20 (20.6) | 0.113 |
Inefficacy | 10 (11.6) | 12 (12.4) | - |
Injection procedure not tolerated | 0 (0.0) | 3 (3.1) | - |
Psychiatric concomitant conditions | 0 (0.0) | 1 (1.0) | - |
Pregnancy | 0 (0.0) | 1 (1.0) | - |
Surgery | 0 (0.0) | 1 (1.0) | - |
Patient moved | 0 (0.0) | 1 (1.0) | Â |